LUGANO, Switzerland • April 13th, 2022 • Swiss based Cerbios-Pharma SA, specialized in the development and manufacturing of chemical and biotechnological APIs, is officially announcing the near finalization of the structure for its new manufacturing building dedicated to High Potency Active Ingredients (HPAPI), which will host 2 additional cGMP production lines for Cytotoxic molecules and additional…
LUGANO, Switzerland • Spring 2022 marked the beginning for Cerbios of a year full of events, finally live. DCAT The kick-off was represented by DCAT, a perfect occasion to update our US partners about the latest improvements in Cerbios capabilities and introduce the recently reorganized Business Team structure: Dr Vítor Sousa – BD Manager for ADCs…
LUGANO, Switzerland • As a pharmaceutical Company, Cerbios is devoted continuously to Innovation: building on our vast experience, we are now ready to jump into the future for the next step development. Probiotics as Pharmaceutical Drug Product For more than 40 years, Cerbios has been manufacturing and commercializing its proprietary strain E. faecium SF68® as a…
LUGANO, Switzerland • Continuous improvement and Innovation are part of the Cerbios DNA, and today, more than ever, a focal point of the Company is Lean Management. Applying Lean principles means working proactively, and the rewards are long lasting both for the Company and its Customers. In line with this simplified approach and to be closer to market…
LUGANO, Switzerland • The Proveo offer of a “one-stop-shop” for Antibody Drug Conjugate (ADC) development, manufacturing and delivery is now restructured as a fully integrated business division of Cerbios-Pharma SA. The restructuring ensures that the service can meet the complex supply chain and program management requirements for successful ADC Drug Product manufacturing, allowing it to provide a…
LUGANO, Switzerland • Pharmaceutical CDMO specialist Cerbios-Pharma SA (Cerbios) will again be a key presence at the 12th World ADC conference Digital San Diego Edition happening from the .11th to the 14th October. Cerbios will be presenting its Proveo division in the CMC stream and in the virtual booth promoting advanced integrated solutions in antibody drug conjugates.…
LUGANO, December 20th, 2019 • Cerbios is proud to announce successful SwissMedic authorization of its new cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs). “The suite further expands Cerbios’ ADCs capacities and consolidates Cerbios commitment to provide best-in-class bioconjugation services for its partners worldwide” says Matteo Piazza Cerbios- Pharma BD…
LUGANO, October 1st, 2019 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Mr. Claudio Pozzoli has been promoted as Chief Operation Officer (COO) and Alberto Terraneo is our new R&D Director. Fausto Vellani (the former COO) has moved to the sister company, strengthening a team that is already achieving excellent results and…
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
